Is HIV-associated tuberculosis a risk factor for the development of cryptococcal disease?

AIDS

Volumn 24, Issue 4, 2010, Pages 612-614

  Jarvis, Joseph N ^a,b,c   Harrison, Thomas S ^a,b   Corbett, Elizabeth L ^d,e   Wood, Robin ^a   Lawn, Stephen D ^a,d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c GF Jooste Hospital   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BACTERIAL ANTIGEN; CATHELICIDIN;

ARTICLE; CD4 LYMPHOCYTE COUNT; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; HUMAN; IMMUNE DEFICIENCY; INNATE IMMUNITY; LUNG TUBERCULOSIS; LYMPHOCYTOPENIA; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; VIRUS LOAD; VITAMIN D DEFICIENCY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; REGRESSION ANALYSIS; RISK FACTORS; SOUTH AFRICA; TUBERCULOSIS, PULMONARY;

EID: 77649255742     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833547f7     Document Type: Article

References (21)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23:525-530.
2. Fessel WJ. Cryptococcal meningitis after unusual exposures to birds. N Engl J Med 1993; 328:1354-1355.
3. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol 1999; 37:3204-3209.
4. Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS 2007; 21:2119-2129.
5. Lawn S, Harries A, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897-1908.
6. Moosa MY, Coovadia YM. Cryptococcal meningitis in Durban, South Africa: a comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients. Clin Infect Dis 1997; 24:131-134.
7. Heyderman RS, Gangaidzo IT, Hakim JG, Mielke J, Taziwa A, Musvaire P, et al. Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. Clin Infect Dis 1998; 26:284-289.
8. Corbett EL, Churchyard GJ, Charalambos S, Samb B, Moloi V, Clayton TC, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002; 34:1251-1258.
9. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009; 48:856-862.
10. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605-1612.
11. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141-2148.
12. Giles SS, Dagenais TR, Botts MR, Keller NP, Hull CM. Elucidating the pathogenesis of spores from the human fungal pathogen Cryptococcus neoformans. Infect Immun 2009; 77:3491-3500.
13. Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski L, Niang R, Casadevall A. Serologic evidence for Cryptococcus neofor-mans infection in early childhood. Pediatrics 2001; 107:E66.
14. Corbett EL, Churchyard GJ, Clayton TC, Williams BG, Mulder D, Hayes RJ, DeCock KM. HIV infection and silicosis: the impact of two potentrisk factorsonthe incidenceofmycobacterial disease in South African miners. AIDS 2000; 14: 2759-2768.
15. Benincasa M, Scocchi M, Pacor S, Tossi A, Nobili D, Basaglia G, et al. Fungicidal activity of five cathelicidin peptides against clinically isolated yeasts. J Antimicrob Chemother 2006; 58: 950-959.
16. Liu PT, Stenger S, Tang DH, Modlin RL. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacter-ium tuberculosis is dependent on the induction of cathelicidin. J Immunol 2007; 179:2060-2063.
17. Corbett EL, Blumberg L, Churchyard GJ, Moloi N, Mallory K, Clayton T, et al. Nontuberculous mycobacteria: defining disease in a prospective cohort of South African miners. Am J Respir Crit Care Med 1999; 160:15-21.
18. Goldman DL, Lee SC, Mednick AJ, Montella L, Casadevall A. Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide. Infect Immun 2000; 68:832-838.
19. Salyer WR, Salyer DC, Baker RD. Primary complex of Crypto-coccus and pulmonary lymph nodes. J Infect Dis 1974; 130:74-77.
20. Vanham G, Toossi Z, Hirsch CS, Wallis RS, Schwander SK, Rich EA, Ellner JJ. Examining a paradox in the pathogenesis of human pulmonary tuberculosis: immune activation and suppression/ anergy. Tuber Lung Dis 1997; 78:145-158.
21. Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159:733-740.